Integrated Drug Discovery Services for the USA

At Domainex, we understand what it means to have a fully integrated approach to drug discovery.

Not only do we provide a full suite of multi-award winning services, from protein production through to lead optimization, but we also operate in a truly global ecosystem, working with clients and suppliers worldwide. Our talented, multi-disciplined team is made up of over a dozen nationalities.

From our base in the university city of Cambridge, UK, we are in a prime location to cater to the US market. With our shared common language and a working day that overlaps with both East and West Coasts, collaborating across the pond is seamless, as proven by our strong established USA client base.

Experience the benefits of partnering with Domainex for free!

Fill out the form below to receive free drug discovery consultancy:

Our US-based Partners

Our Fully Integrated Services

Domainex offers a range of drug discovery services to support you along every stage of the drug discovery journey, from disease target nomination to candidate drug selection. Our dedicated project leaders will work collaboratively with you to provide tailored, outcome-based solutions. This integrated approach has a proven record of success in delivering timely and cost-effective results on behalf our clients, including the generation of new intellectual property.

Key Benefits of Working With Us

Shared common language

With no language barrier in UK–USA partnerships, communication is simple and efficient

Progress around the clock

Our overlapping working days combined with the commitment and flexibility of our team means our scientists will interact directly with you during your working day, and leave you safe in the knowledge that we are working hard on your behalf before your working day begins

Full capabilities

With our fully integrated services and state-of-the-art on-site facilities, outsourcing management is made simple. Our rapid design-make-test cycles enable project milestones to be achieved as quickly as possible.

Highly skilled scientists

Our team is built around experienced scientists from across multiple disciplines, who are capable of tackling the most difficult challenges, will propose innovative solutions, and will contribute valuable intellectual input to your project

Vibrant UK life sciences

By being a part of the UK’s world-leading life sciences scene, you can have a high degree of certainty of continuity of service — a valued asset in times of heightened geopolitical uncertainty

Clear ownership of IP

Your IP is safe in our hands, guaranteeing you full ownership of, and exclusive rights to, your research results and products.

Frequently Asked Questions

How do you work with international clients?

Our scientists are based at our research centers in Cambridge, UK, benefiting from a wealth of scientific expertise and talent in the local area. We are ideally placed to service global clients and can arrange meetings to suit your time zone, whether you’re based in the US, Europe or Asia.

We chose to base our USA office in Cambridge, MA, as it mirrors Cambridge UK’s commitment to life science research and is surrounded by other flourishing organizations. Our scientists regularly attend conferences and events across the US and North America and so can meet in person as needed, or you’re welcome to arrange a visit to our research centers of excellence in the UK

Do you deliver internationally?

Yes, we routinely ship compounds and proteins to our international customers. We can use one of our preferred couriers or use the courier of your choosing.

What proportion of your clients are based in the US?

Domainex is a truly international organization. Our team speak many different languages including French, Spanish, Italian and German and we have clients all over the world. Currently, ~30% of our business comes from US based customers.

Why should we work with Domainex?

We understand the complexities of the drug discovery process. Our integrated offering means we can provide the right service for your project, no matter what stage it is at, and our scientists share data and learnings to drive the projects forward efficiently without the risk of siloed information. Your organization benefits from access to an expert team, our own innovative technology as well as the latest scientific instrumentation. You’ll be assigned a project manager to ensure the process runs smoothly.

With our fully integrated services and state-of-the-art on-site facilities, outsourcing is made simple. Our rapid design-make-test cycles enable project milestones to be achieved as quickly as possible.

Our team is built around experienced scientists in multiple disciplines, who are capable of tackling the most difficult challenges, will propose innovative solutions, and will contribute valuable intellectual input to your project.

Why work with a UK-based drug discovery CRO?

he UK has a flourishing life sciences industry, supported by a wealth of leading academic institutions and a highly skilled talent pipeline. Domainex is based within the UK’s Golden Triangle, which includes the research hotspots of Cambridge, Oxford and London. Our team are surrounded by the latest discoveries in the pharmaceutical and biotech industries, enabling them to incorporate the latest innovations and drive progress for our clients.

With no language barrier and overlapping work days, communication is simple and efficient.

By being a part of the UK’s world-leading life sciences scene, you can have a high degree of certainty of continuity of service — a valued asset in times of heightened geopolitical uncertainty. You will have full ownership of, and exclusive rights to, your research results and products, providing IP protection for future commercialization.

Protein Production & Target Generation

We offer complete protein science solutions, including construct design, cloning, expression, purification & characterization. For challenging proteins, our proprietary Combinatorial Domain Hunting (CDH) technology can quickly identify soluble, highly expressible protein constructs which are suitable for use in assays or for structural biology, and our PoLiPa platform allows efficient preparation of stable and highly purified membrane proteins. Our structural biologists can generate high-resolution X-ray crystal structures providing invaluable information for your program and enabling structure based drug design (SBDD) as your project progresses.

Hit Identification

We use several rapid and cost-effective techniques for hit identification. We deploy fragment-based drug design (FBDD), virtual screening, high throughput screening (HTS) or literature-to-lead approaches to generate novel chemical matter. Our cost-effective hit identification platforms will gain you an early edge over competitors and are supported by a full suite of assay biology services, including biophysical, biochemical and cell-based assay development and screening.

Hit-to-lead and Lead Optimisation

By rapidly establishing the potential of each of your hits, we can focus our lead optimization work on the most promising chemical series. Our medicinal and computational chemists use best-in-class molecular docking and physicochemical property prediction software to inform their design process before the compounds are synthesized in our laboratories. Once synthesized, compounds are tested in carefully designed screening cascades, which include in vitro pharmacology and ADME assays, to ensure that only those compounds with the highest chances of success are progressed. Our talented team will constantly assess and revise the cascade to adapt it to your evolving project, incorporating PK and efficacy studies, when appropriate. Our structural biologists will generate high-resolution X-ray crystal structures of your protein target bound to compounds of interest, providing invaluable information to guide the optimization process. As your project progress through lead optimization, our team can produce larger compound batches, in our onsite scale up facility, to enable efficacy and toxicity studies, in higher species, to be performed.

We carefully design and then thoroughly test each compound that we make, aiming to simultaneously optimize all aspects of the target product profile (TPP). By doing this, your drug candidate will be delivered with the smallest number of iterations possible, saving you both time and money.

If you would like to know more about Domainex’s discovery services, or speak to us regarding your own drug discovery needs, please contact us at: USA-enquiries@domainex.co.uk

Find out more about our integrated drug discovery services in the US

From our UK base, we deliver a suite of advantages to make medicines research effective and efficient for our American clients. Discover more about working with Domainex to enrich your medicines pipeline.

Download brochure

All of our interactions with Domainex have been extremely positive and we are impressed with the molecules they have discovered.

Jeffery Miller

CSO & CEO, Invivoscribe, San Diego

The Domainex scientists have contributed strategic insight and intellectual input across a range of disciplines. This support was invaluable in areas of expertise on the overall drug discovery process. I’ve really enjoyed working together with such a dedicated, highly skilled and professional team. I would recommend Domainex to anyone looking for a provider of drug discovery services.

Professor Helen Philippou

Professor of Translational Medicine, Lunac Therapeutics

We have been really impressed with the service at Domainex, from initial discussion to delivery of the project. The Domainex team are attentive, well organised, and knowledgeable. They always take the time to understand our exact needs and consistently deliver high-quality results, in a time efficient manner.

Dr Jack Kennefick

Co-founder & Chief Executive Officer, Tagomics

It has been an absolute pleasure working with Dr Boffey and the Domainex team on this project. Without their first class medicinal chemistry expertise and the use of their Leadbuilder virtual screening platform at the outset of the programme, we would not have been able to secure the support of The Wellcome Trust and advance the programme to the stage it has now reached.

Professor Daniel Longley

Deputy Director of the Patrick G. Johnston Centre for Cancer Research, Queen’s University Belfast